Omeros Rises as Novo Nordisk Deal Boosts Q4 Earnings

Omeros’ stock jumped ~14% last week, its best intraday gain since December, after reporting stronger-than-expected Q4 2025 earnings, driven largely by the upfront payment from its partnership with Novo Nordisk. The Seattle-based biotech’s shares surged in October when Novo secured exclusive global rights to Omeros’ rare disease therapy, zaltenibart, in a deal worth up to $2.1B.